The market size of the Global Cell Free Protein Synthesis Market in the year 2021 is valued at 239.91 million and is predicted to reach 412.32 million by the year 2030 at an 6.37% CAGR during the forecast period.
Cell-free protein is a valuable tool for molecular biologists in basic and applied sciences. Researchers in high-throughput functional proteomics and genomics increasingly use cell-free protein synthesis because it has considerable benefits over protein expression in living cells. The expanding R&D in proteomics and genomics, the increased prevalence of cancer and infectious disorders, and shorter-expression time and structural modification are all key drivers driving the growth of the cell-free protein synthesis market. Cell lysates are used in cell-free protein synthesis to produce the desired recombinant proteins. The lack of eukaryotic co- and post-translational modifications is one of the key roadblocks to the future expansion of the cell-free protein synthesis sector. Other key contributors include increased R&D outsourcing by biotechnological and pharmaceutical businesses, lower patent cliff revenues resulting in greater pharmaceutical sector research intensity, lower research productivity, and rising biosimilar development investment.
Furthermore, the recent increase in infectious disorders, such as lower respiratory infections and human immunodeficiency virus (HIV), due to climate change, changing land-use patterns, and fast urbanization are likely to boost market expansion. Furthermore, because of the brief reaction scales that result in the limited ability of resultant protein folding during protein expression, the addition of energy and substrate sources in the process can impact cell-free protein synthesis systems.
The cell-free protein synthesis market is segmented on the product, application and end-use. Based on product, the market is divided into accessories, consumables, and lysate systems (E.coli Lysate, Wheat Germ Extract Lysate, Insect Cell Lysate, Human Cell Lysate, Rabbit Reticulocyte Lysate, and Other Lysate Systems). Based on application, the Cell-free protein synthesis market is segmented into enzyme engineering, protein labeling, protein-protein interaction, high throughput production and other application. Based on end-use, the cell-free protein synthesis market is segmented into pharmaceutical & biotechnology companies, academics & research institutes, and others.
Based on product, the lyscale systems segment is accounted as a major contributor to the cell-free protein synthesis market
Lyscale systems segment is expected to hold a significant market share during the forecast period. Lysates are free of endogenous genetic signals and have several advantages, including high protein production and tolerance to most additions. In addition, E. In recombinant approaches, coli-based systems are utilized to create a variety of biological medicines, including insulin. Continuous use has allowed for investigating the interactions and tolerability of E byproducts. coli-based methods. A substantial body of current scientific literature permits its quick adoption by industry and academia.
The pharmaceutical & biotechnology companies segment witnessed growth at a rapid rate.
The pharmaceutical & biotechnology companies grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. The increase in biopharmaceutical manufacturing capacities promotes the demand for cell free protein synthesis products. The construction of GMP facilities will meet the growing demand for contract development and manufacturing firms. It will also address the need for a greater range of raw materials and manufacturing methods. Regenerative medicines, RNA and DNA vaccines, cancer immunotherapy medications, and gene therapy will all be manufactured.
The North American cell-free protein synthesis market holds a significant revenue share in the region
The North American cell-free protein synthesis market is expected to register the highest market share in revenue soon. The United States has the largest market share in the North American region due to factors such as the increasing burden of cancer cases in the country, which is expected to stimulate demand for the cell-free protein synthesis market. The rising incidences of chronic diseases such as the aging population, and cancer, the growing need for targeted and customized medication, major R&D facilities, and favorable government initiatives in the United States. In addition, Asia Pacific is projected to grow rapidly in the global cell-free protein synthesis market. In Asia, cell-based research is gaining traction in academia and the biotechnology industry. The increased R&D investment in the region drives the market's significant expansion.
The key players in the cell free protein synthesis market have shifted their focus toward product manufacturing and are initiating significant strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance their product portfolio and strengthen their global market footprint. Some major key players in the Cell free protein synthesis market are Biotech rabbit, Genocopies, Inc., New England Biolabs, Merck Kagan, Promega Corporation., Jena Biosciences GmbH,Creative Biolabs., BioCentury Inc., Bioneer Corporation., Sutro Biopharma, Inc.